Ofatumumab

Last updated

Ofatumumab
Ofatumumab 3GIZ.png
Fragment antigen-binding of ofatumumab ( PDB: 3GIZ ​)
Monoclonal antibody
Type Whole antibody
Source Human
Target CD20
Clinical data
Trade names Arzerra, Kesimpta
Other namesHuMax-CD20, OMB157
AHFS/Drugs.com Monograph
MedlinePlus a621050
License data
Pregnancy
category
Routes of
administration 		Intravenous (Arzerra), subcutaneous (Kesimpta)
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life 14 days
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C6480H10022N1742O2020S44
Molar mass 146062.27 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [12] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. [8] [10] Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. [13] It is sold by Novartis under license from Genmab. [14]

Contents

The most common side effects for ofatumumab (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions. [8] The most common side effects for ofatumumab (Arzerra) include infusion reactions and neutropenia. [13]

Medical uses

Ofatumumab (Kesimpta 20 mg solution for injection in pre-filled syringe/pen) is indicated for the treatment of relapsing forms of multiple sclerosis in adults. [8] [10] [15] The recommended dose is 20 mg of ofatumumab administered by subcutaneous injection with monthly dosing following loading. [16] [17]

Treatment with ofatumumab has been shown to rapidly deplete B-cells [16] [17] which aids MS pathogenesis by influencing and regulating different autoimmune process such as T-cell production and APC activity. [18] Depleted B-cells are required to address chronic clinical conditions like MS.

Ofatumumab (Arzerra 100 mg or 1000 mg concentrate for solution for infusion) is indicated for the treatment of untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL). [7] [19] [4] [20] The recommended doses for treatment of CLL are higher than MS, with 1000 or 2000 mg infusions administered monthly depending on if the CLL is untreated, relapsed or refractory, following loading. [20]

Ofatumumab is under investigation as a potential treatment for follicular lymphoma, diffuse large B cell lymphoma and rheumatoid arthritis.[ citation needed ]

Adverse effects

Adverse effects of ofatumumab (Kesimpta) by frequency: [21] [17]

Very common (>10% frequency):

Common (1-10% frequency):

Adverse effects of ofatumumab (Arzerra) by frequency: [7] [13] [4]
Very common (>10% frequency):

Common (1-10% frequency):'

Uncommon (0.1-1% frequency):

Rare (<0.1% frequency):

Ofatumumab (Arzerra) has received a black box warning regarding the potential for it to cause progressive multifocal leukoencephalopathy and hepatitis B reactivation. [15] [22] Likewise it is also advised that doctors watch cautiously for small bowel obstruction, neutropenia, thrombocytopenia, infusion reactions or an increased risk for infection. [22]

For more information, please refer to the prescribing information or your doctor.

Interactions

No formal drug interaction studies have been conducted with ofatumumab. [7] Although it is advised that patients are not administered live virus vaccines (e.g. the oral polio vaccine) while undergoing treatment with ofatumumab due to the compromised ability to fight the attenuated viruses seen in patients being treated with ofatumumab. [22] While on treatment with ofatumumab (Kesimpta), all immunizations should be administered according to immunization guidelines at least 4 weeks prior to initiation of ofatumumab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ofatumumab for inactivated vaccines. [21]

Mechanism

Ofatumumab is a fully human anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab. [23] Ofatumumab binds to a distinct epitope on small and large extracellular loops of CD20. [24] [25] The CD20 antigen is expressed on solely B cell lymphocytes. [23] Compared with rituximab, ofatumumab binds more tightly to CD20 with a slower off-rate. [23] It causes cytotoxicity in the cells that express CD20 by means of complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). [23]

History

Ofatumumab was jointly developed by Danish biotech Genmab and GlaxoSmithKline GSK plc who entered into an agreement to co-develop and commercialize ofatumumab in 2006. [26] It was approved as Arzerra for the treatment of chronic lymphocytic leukemia in the United States in October 2009. [27] [28]

Ofatumumab (Arzerra) was then approved in the European Union in June 2010, [13] in the United Kingdom in April 2010, [4] and in Canada in August 2012. [29] [30]

In 2014, Novartis acquired a number of GSK's oncology products, including the collaboration with Genmab and ofatumumab. [14] [31]

For commercial reasons ofatumumab (Arzerra) was withdrawn from the Canadian market in 2017. [29] [30] It was withdrawn from the European Union in February 2019. [32] [33] Novartis removed it from all of the non-US markets and made it available only for compassionate use in those markets. [34] [35]

Ofatumumab (Kesimpta) was approved for the treatment of relapsing forms of multiple sclerosis in adults in the United States in August 2020. [36] [37] EU approval was subsequently received in March 2021. [10]

Society and culture

Economics

Ofatumumab (Arzerra) was transitioned to an oncology access program to make it available at no cost to chronic lymphocytic leukemia patients in the U.S. [38]

Related Research Articles

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

<span class="mw-page-title-main">Rituximab</span> Biopharmaceutical drug

Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza, Rixathon, Ruxience, and Truxima.

<span class="mw-page-title-main">Natalizumab</span> Medication used to treat multiple sclerosis and Crohns disease

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

<span class="mw-page-title-main">Cladribine</span> Pharmaceutical drug

Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

<span class="mw-page-title-main">Alemtuzumab</span> Medication

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A.

Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody.

<span class="mw-page-title-main">Ibrutinib</span> Medication used in cancer treatment

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib also binds to C-terminal Src Kinases. These are off-target receptors for the BTK inhibitor. Ibrutinib binds to these receptors and inhibits the kinase from promoting cell differentiation and growth. This leads to many different side effects like left atrial enlargement and atrial fibrillation during the treatment of Chronic Lymphocytic Leukemia.

<span class="mw-page-title-main">Idelalisib</span> Chemical compound

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers.

<span class="mw-page-title-main">Acalabrutinib</span> Chemical compound

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings.

<span class="mw-page-title-main">Duvelisib</span> PI3K inhibitor

Duvelisib, sold under the brand name Copiktra, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. It is taken by mouth. It is a PI3 kinase inhibitor.

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer.

<span class="mw-page-title-main">Zanubrutinib</span> Chemical compound

Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.

Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL).

Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.

Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech.

Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab.

References

  1. ↑ "Ofatumumab (Arzerra) Use During Pregnancy". Drugs.com. 29 January 2020. Retrieved 22 August 2020.
  2. 1 2 "AusPAR: Ofatumumab". Therapeutic Goods Administration (TGA). 19 August 2021. Retrieved 10 September 2021.
  3. ↑ "Summary for ARTG Entry:196945 Arzerra ofatumumab (rmc) 100mg/5mL injection concentrate vial". Therapeutic Goods Administration (TGA). Archived from the original on 28 August 2021. Retrieved 23 August 2020.
  4. 1 2 3 4 "Arzerra (acetate formulation) -Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 27 November 2013. Archived from the original on 4 March 2016. Retrieved 24 January 2014.
  5. ↑ "Kesimpta 20 mg solution for injection in pre-filled pen - Patient Information Leaflet (PIL)". (emc). 14 April 2021. Retrieved 16 April 2021.
  6. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  7. 1 2 3 4 "Arzerra- ofatumumab injection, solution". DailyMed. 22 June 2020. Retrieved 21 August 2020.
  8. 1 2 3 4 "Kesimpta- ofatumumab injection, solution". DailyMed. 20 August 2020. Retrieved 23 August 2020.
  9. ↑ "Arzerra EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 21 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. 1 2 3 4 "Kesimpta EPAR". European Medicines Agency (EMA). 25 January 2021. Retrieved 16 April 2021.
  11. ↑ "Kesimpta Product information". Union Register of medicinal products. Retrieved 3 March 2023.
  12. ↑ Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. (August 2020). "Ofatumumab versus Teriflunomide in Multiple Sclerosis". The New England Journal of Medicine. 383 (6): 546–557. doi: 10.1056/nejmoa1917246 . hdl: 11573/1473907 . PMID   32757523. S2CID   221015936.
  13. 1 2 3 4 "Arzerra : EPAR - Product Information" (PDF). European Medicines Agency. 7 March 2013. Archived from the original (PDF) on 4 February 2014. Retrieved 24 January 2014.
  14. 1 2 "Genmab To Transfer Ofatumumab From GSK To Novartis". www.bioprocessonline.com. Retrieved 31 October 2022.
  15. 1 2 "Boxed Warning and new recommendations to decrease risk of hepatitis B". U.S. Food and Drug Administration. 21 June 2019. Retrieved 11 September 2021.
  16. 1 2 "Kesimpta EPAR" (PDF). European Medicines Agency (EMA). Retrieved 31 October 2022.
  17. 1 2 3 "Prescribing Information Kesimpta" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 31 October 2022.
  18. ↑ Arneth BM (June 2019). "Impact of B cells to the pathophysiology of multiple sclerosis". Journal of Neuroinflammation. 16 (1): 128. doi: 10.1186/s12974-019-1517-1 . PMC   6593488 . PMID   31238945.
  19. ↑ "Arzerra EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 31 October 2022.
  20. 1 2 "Arzerra (ofatumumab) Information". U.S. Food and Drug Administration (FDA). 3 November 2018. Retrieved 31 October 2022.
  21. 1 2 "Kesimpta - Summary of Product Characteristics (SPC)" (PDF). European Medicines Agency (EMA). Retrieved 31 October 2022.
  22. 1 2 3 "Arzerra (ofatumumab) dosing, indications, interactions, and more". Medscape Reference. WebMD. Retrieved 24 January 2014.
  23. 1 2 3 4 Lin TS (2010). "Ofatumumab: a novel monoclonal anti-CD20 antibody". Pharmacogenomics and Personalized Medicine. 3: 51–59. doi: 10.2147/PGPM.S6840 . PMC   3513208 . PMID   23226042.
  24. ↑ Anonymous Referee #2 (26 September 2016). "Interactive comment on "Sensitivity of the Variability of Mineral Aerosol Simulations to Meteorological Forcing Datasets" by Molly B. Smith et al". Atmospheric Chemistry and Physics. doi: 10.5194/acp-2016-638-rc1 .
  25. ↑ Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. (July 2006). "The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20". Journal of Immunology. 177 (1): 362–371. doi: 10.4049/jimmunol.177.1.362 . PMID   16785532. S2CID   24974085.
  26. ↑ "Genmab - Global Agreement for Humax-CD20". Genmab - Global Agreement for Humax-CD20. Retrieved 31 October 2022.
  27. ↑ "Drug Approval Package:Arzerra (Ofatumumab) Injection Application: 125326". U.S. Food and Drug Administration (FDA). 21 January 2010. Retrieved 21 August 2020.
  28. ↑ "Arzerra (ofatumumab) FDA Approval History". Drugs.com. 26 October 2009. Retrieved 21 August 2020.
  29. 1 2 "Arzerra Product information 86740". Drug Product Database. 25 April 2012. Retrieved 21 August 2020.
  30. 1 2 "Arzerra Product information 86741". Drug Product Database. 25 April 2012. Retrieved 21 August 2020.
  31. ↑ "GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis". GSK (Press release). Retrieved 31 October 2022.
  32. ↑ "Arzerra: Withdrawn application". European Medicines Agency (EMA). 17 September 2018. Retrieved 21 August 2020.
  33. ↑ "Arzerra: Withdrawal of the marketing authorisation in the European Union" (PDF). European Medicines Agency. 28 February 2019.
  34. ↑ "Novartis Withdraws Chronic Leukemia Drug Arzerra From Non-U.S. Markets". FDANews. 30 January 2018. Retrieved 21 August 2020.
  35. ↑ "Novartis to transition use of Arzerra to compassionate use outside US". EPM Magazine. 22 January 2018. Retrieved 21 August 2020.
  36. ↑ "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Retrieved 21 August 2020.
  37. ↑ "Ofatumumab (Kesimpta) FDA approval letter" (PDF).
  38. ↑ "Genmab Announces Plan to Transition Arzerra (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S. Copenhagen Stock Exchange:GEN" (Press release). Genmab A/S. 20 August 2020. Retrieved 16 April 2021– via GlobeNewswire.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.